STRATA Skin Sciences Names Michael E. Goodman as Head of International Sales
May 16 2022 - 4:05PM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology
company dedicated to developing, commercializing and marketing
innovative products for the treatment of dermatologic conditions,
today announced that Michael E. Goodman has been named STRATA’s
Head of International Sales.
In this newly created role, Mr. Goodman will be a key member of
STRATA's expanding global commercial leadership team, with
oversight of the Company’s commercial and sales strategy in Europe,
Asia, and Latin America. In addition, as the Head of International
Sales, Mr. Goodman assumes responsibility for providing STRATA with
key insights into successful sales strategies for international
expansion and to drive these strategies to fruition across targeted
global markets.
“We are delighted to welcome Michael to the STRATA team,” said
Bob Moccia, Chief Executive Officer of STRATA. “He brings
expansive, and highly relevant sales and operational management
experience to our leadership team, which will be key to our
international expansion success. We believe that his experience in
the medical laser space, particularly in dermatology and
aesthetics, will be an important asset for STRATA to leverage. We
look forward to supporting his growth and vision for our
company.”
Mr. Goodman’s experience in international sales includes his
position as Associate Director of International Sales for Obagi
Medical Products where he led, reset, and supported a network of
global distribution partners. Most recently, he was a U.S. regional
sales director for Pulse Biosciences, advancing commercialization
efforts and strategic direction. Earlier, Mr. Goodman founded MG
Consulting Group, advising on industry, sales training, and product
expertise to organizational leadership in the medical device
industry. His career also includes various International and
domestic sales and marketing positions with Syneron-Candela and for
more than a decade, with Sound Surgical Technologies, which was
subsequently acquired by Solta Medical. Upon Solta Medical’s
acquisition by Valeant Pharmaceuticals, he led the international
surgical specialties and global distribution channels for
Valeant.
“I am excited to join STRATA and support its
growth by increasing its international presence,” said Mr. Goodman.
“I have been in the medical laser therapy space for nearly two
decades, and I look forward to leveraging that experience to aid
STRATA in further building its international sales strategy and
exposure among distributors and dermatologists.”
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company in dermatology dedicated
to developing, commercializing and marketing innovative products
for the in-office treatment of dermatologic conditions. Its
products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos®
excimer lasers, VTRAC® lamp systems, and TheraClear treatment
system utilized in the treatment of psoriasis, vitiligo, acne and
various other skin conditions.
The Company’s proprietary XTRAC, XTRAC Momentum™ 1.0 and Pharos
excimer lasers deliver a highly targeted therapeutic beam of UVB
light to treat psoriasis, vitiligo, eczema, atopic dermatitis and
leukoderma, diseases which impact over 31 million patients in the
United States alone. The technology is covered by multiple patents.
Additionally, STRATA’s recently acquired assets related to
Theravant Corporation’s TheraClear system allows the company to
expand into the U.S. acne care market.
STRATA’s unique business model in the U.S. leverages targeted
Direct to Consumer (DTC) advertising to generate awareness and
utilizes its in-house call center and insurance advocacy teams to
increase volume for the Company’s partner dermatology clinics.
Investor ContactJack Droogan(203)
585-4140ir@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024